Your browser doesn't support javascript.
loading
Defining secondary progressive multiple sclerosis.
Lorscheider, Johannes; Buzzard, Katherine; Jokubaitis, Vilija; Spelman, Tim; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Izquierdo, Guillermo; Girard, Marc; Duquette, Pierre; Prat, Alexandre; Lugaresi, Alessandra; Grand'Maison, François; Grammond, Pierre; Hupperts, Raymond; Alroughani, Raed; Sola, Patrizia; Boz, Cavit; Pucci, Eugenio; Lechner-Scott, Jeanette; Bergamaschi, Roberto; Oreja-Guevara, Celia; Iuliano, Gerardo; Van Pesch, Vincent; Granella, Franco; Ramo-Tello, Cristina; Spitaleri, Daniele; Petersen, Thor; Slee, Mark; Verheul, Freek; Ampapa, Radek; Amato, Maria Pia; McCombe, Pamela; Vucic, Steve; Sánchez Menoyo, José Luis; Cristiano, Edgardo; Barnett, Michael H; Hodgkinson, Suzanne; Olascoaga, Javier; Saladino, Maria Laura; Gray, Orla; Shaw, Cameron; Moore, Fraser; Butzkueven, Helmut; Kalincik, Tomas.
Afiliação
  • Lorscheider J; 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
  • Buzzard K; 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia 3 Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.
  • Jokubaitis V; 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
  • Spelman T; 1 Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Havrdova E; 4 Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Horakova D; 4 Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Trojano M; 5 Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.
  • Izquierdo G; 6 Hospital Universitario Virgen Macarena, Seville, Spain.
  • Girard M; 7 Hôpital Notre Dame, Montreal, Canada.
  • Duquette P; 7 Hôpital Notre Dame, Montreal, Canada.
  • Prat A; 7 Hôpital Notre Dame, Montreal, Canada.
  • Lugaresi A; 8 Department of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum - Università di Bologna, Bologna, Italy 9 IRCCS Istituto delle Scienze Neurologiche - "UOSI Riabilitazione Sclerosi Multipla" Bologna, Italy.
  • Grand'Maison F; 10 Neuro Rive-Sud, Hôpital Charles LeMoyne, Greenfield Park, Canada.
  • Grammond P; 11 Hôtel-Dieu de Lévis, Lévis, Canada.
  • Hupperts R; 12 Orbis Medical Center, Sittard, The Netherlands.
  • Alroughani R; 13 Amiri Hospital, Kuwait, Kuwait.
  • Sola P; 14 Nuovo Ospedale Civile S.Agostino/Estense, Modena, Italy.
  • Boz C; 15 Karadeniz Technical University, Trabzon, Turkey.
  • Pucci E; 16 Neurology Unit, ASUR Marche, AV3, Macerata, Italy.
  • Lechner-Scott J; 17 Department of Neurology, John Hunter Hospital, Newcastle, Australia 18 School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
  • Bergamaschi R; 19 Mondino National Neurological Institute of Pavia, Italy.
  • Oreja-Guevara C; 20 University Hospital San Carlos, Madrid, Spain.
  • Iuliano G; 21 Ospedali Riuniti di Salerno, Salerno, Italy.
  • Van Pesch V; 22 Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Granella F; 23 University of Parma, Parma, Italy.
  • Ramo-Tello C; 24 Hospital Germans Trias i Pujol, Badalona, Spain.
  • Spitaleri D; 25 AORN San Giuseppe Moscati, Avellino, Italy.
  • Petersen T; 26 Kommunehospitalet, Aarhus, Denmark.
  • Slee M; 27 Flinders University and Flinders Medical Centre, Adelaide, Australia.
  • Verheul F; 28 Groene Hart Ziekenhuis, Gouda, The Netherlands.
  • Ampapa R; 29 Nemocnice Jihlava, Jihlava, Czech Republic.
  • Amato MP; 30 University of Florence, Florence, Italy.
  • McCombe P; 31 The University of Queensland, Brisbane, Australia.
  • Vucic S; 32 Westmead Hospital, Sydney, Australia.
  • Sánchez Menoyo JL; 33 Hospital de Galdakao-Usansolo, Galdakao, Spain.
  • Cristiano E; 34 Hospital Italiano, Buenos Aires, Argentina.
  • Barnett MH; 35 Department of Medicine, University of Sydney, Sydney, Australia.
  • Hodgkinson S; 36 Liverpool Hospital, Liverpool, Australia.
  • Olascoaga J; 37 Hospital Universitario Donostia, San Sebastian, Spain.
  • Saladino ML; 38 Instituto de Neurosciencias INEBA, Buenos Aires, Argentina.
  • Gray O; 39 South Eastern Trust, Belfast, Northern Ireland.
  • Shaw C; 40 Geelong Hospital, Geelong, Australia.
  • Moore F; 41 Jewish General Hospital, Montreal, Canada.
  • Butzkueven H; 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia 3 Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia butz@unimelb.edu.au.
  • Kalincik T; 1 Department of Medicine, University of Melbourne, Melbourne, Australia 2 Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
Brain ; 139(Pt 9): 2395-405, 2016 09.
Article em En | MEDLINE | ID: mdl-27401521
ABSTRACT
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Índice de Gravidade de Doença / Progressão da Doença / Esclerose Múltipla Crônica Progressiva Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Índice de Gravidade de Doença / Progressão da Doença / Esclerose Múltipla Crônica Progressiva Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article